Gosset Furiex Pharmaceuticals General Information
Furiex developed eluxadoline, a locally acting mu opioid receptor agonist/delta antagonist aimed at treating IBS-D symptoms. The company was preparing an NDA submission in late Q3 of 2014. They also advanced JNJ-Q2, a broad-spectrum fluoroquinolone antibiotic licensed from Janssen Pharmaceutica, through successful Phase II trials targeting ABSSSI and CABP[2][4][5].
Contact Information
United States
Drug Pipeline
Key Partnerships
Forest Laboratories acquired Furiex in a deal valued at approximately $1.1 billion plus contingent value rights related to eluxadoline’s regulatory status[2][4]., Royalty Pharma purchased royalties on other Furiex products like alogliptin and Priligy from Forest post-acquisition[2][4]., Janssen Pharmaceutica had licensed out rights to the compound JNJ-Q2 but did not continue development themselves[5].
Furiex Pharmaceuticals Funding
No funding data available